We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Non-Invasive Blood Test for Colon Cancer Presented at 2021 AACC Annual Scientific Meeting

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

A new non-invasive test that uses blood samples to diagnose cases of colorectal cancer was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

The test developed by researchers at the Medical Research Institute (Alexandria, Egypt) could facilitate screening efforts for colorectal cancer. Colorectal cancer is one of the leading causes of death from cancer worldwide, and detecting the disease early is essential for a good prognosis. Although colonoscopies are the most effective tools for diagnosis, many patients avoid getting them due to their invasive nature. Other tests such as those for occult blood in stool are less invasive, but don’t have the same accuracy and performance, and can yield false positives that lead to unnecessary follow-up colonoscopies for patients.

The new non-invasive blood test may help identify cases of colorectal cancer and improve patient compliance with screening. Using multiplex bead technology, the researchers examined levels of the inflammatory proteins eotaxin-1, MIP-1 beta, G-CSF, VEGF-A, and Fas ligand in 35 patients with colorectal cancer and 52 individuals without cancer. The first four proteins were elevated in the cancer patients, suggesting these proteins could serve as potential biomarkers for future screening efforts. The researchers also found that the multiplex bead test outperformed routine stool occult blood tests.

“The main novel aspect of our study is the use of multiplex technology in simultaneous measuring of serum-based biomarkers in [colorectal cancer] diagnosis, which will reduce cost and time,” said Dr. Mona Eldeeb of the Medical Research Institute who led the team. “The overall performance of the studied serum biomarkers is much better than routinely used occult blood in screening [colorectal cancer].”

Related Links:
Medical Research Institute 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Coagulation Analyzer
CS-2400
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article
ADLM

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.